Biomarkers for Alzheimer¿s Disease Drug Development

1. Auflage 2018
ISBN: 978-1-4939-7703-1
Verlag: Springer

Buch, Englisch, Band 1750, 372 Seiten, HC runder Rücken kaschiert, Format (B × H): 183 mm x 260 mm, Gewicht: 932 g

Reihe: Methods in Molecular Biology

This volume aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer’s disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimer’s disease, cutting-edge developments in neuropathology and their relevance for Alzheimer’s disease trials, novel genomic strategies for biomarker development, and related topics including neuropsychological testing and advanced analytical methods.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.

 

Authoritative and cutting-edge, Biomarkers for Alzheimer's Disease Drug Development aims to ensure successful results in the further study of this vital field.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Perneczky, Robert

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Alzheimer und Demenz

Inhaltsverzeichnis

Epidemiology of Dementia: The Burden on Society, the Challenges for Research.- Population-based Approaches to Alzheimer’s Disease Prevention.- Systems Biology Methods for Alzheimer’s Disease Research towards Molecular Signatures, Subtypes and Stages and Precision Medicine. Application in Cohort Studies and Trials.- CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform.- CSF N-glycomics using MALDI MS Techniques in Alzheimer’s Disease.- MicroRNA Profiling of Alzheimer’s Disease Cerebrospinal Fluid.- Validation of a Chemiluminescence Immunoassay for Measuring  Amyloid-ß in Human Blood Plasma.- Mass Spectrometry-based Metabolomic Multiplatform for Alzheimer’s Disease Research.- Blood-based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis within the Dimensional Spectrum of Neurodegenerative Diseases.- Functional Magnetic Resonance Imaging in Alzheimer’ Disease Drug Development.- Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies.- Hybrid PET-MRI in Alzheimer’s Disease Research.- Amyloid PET Imaging: Standardization and Integration with Other Alzheimer Disease Biomarkers.- The use of 18F-FDG PET in the Diagnostic Workup of Alzheimer’s Dementia.- Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron Emission Tomography.- Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.- Unbiased Lipidomics and Metabolomics of Human Brain Samples.- Neuropathological Assessment as an Endpoint in Clinical Trial Design.- Analysis of micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer’s Disease Biomarker Discovery.- Telomere length shortening in Alzheimer’s disease – procedures for a causal investigation using single nucleotide polymorphisms in a Mendelian Randomization study.- Quantifying miRNA Deregulation in Alzheimer’s Disease.- Imaging of Microglial Activation in Alzheimer’s Disease by [11C]PBR28 PET.- In Vivo Two-photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models.- Cognitive Assessment in Alzheimer’s Disease Clinical Trials.- Data Mining and Machine Learning Methods for Dementia Research.